Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Cost-effectiveness of posaconazole compared with standard azole therapy for prevention of invasive fungal infections in patients at high risk in Switzerland.

Greiner RA, Meier Y, Papadopoulos G, O'Sullivan AK, Imhof A.

Oncology. 2010;78(3-4):172-80. doi: 10.1159/000313696. Epub 2010 Apr 23.

PMID:
20414005
2.

[Cost effectiveness of posaconazole versus fluconazole/itraconazole in the prophylactic treatment of invasive fungal infections in Mexico].

Rely K, Alexandre PK, Escudero GS.

Value Health. 2011 Jul-Aug;14(5 Suppl 1):S39-42. doi: 10.1016/j.jval.2011.05.032. Spanish.

3.

Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands.

Stam WB, O'Sullivan AK, Rijnders B, Lugtenburg E, Span LF, Janssen JJ, Jansen JP.

Eur J Haematol. 2008 Dec;81(6):467-74. doi: 10.1111/j.1600-0609.2008.01141.x.

PMID:
18754857
5.

Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT.

de la Cámara R, Jarque I, Sanz MA, Grau S, Casado MA, Sabater FJ, Carreras E.

Bone Marrow Transplant. 2010 May;45(5):925-32. doi: 10.1038/bmt.2009.272. Epub 2009 Oct 5. Erratum in: Bone Marrow Transplant. 2010 May;45(5):966.

PMID:
19802030
6.

Economic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in Sweden.

Lundberg J, Höglund M, Björkholm M, Åkerborg Ö.

Clin Drug Investig. 2014 Jul;34(7):483-9. doi: 10.1007/s40261-014-0199-9.

PMID:
24820968
7.

Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease.

O'Sullivan AK, Weinstein MC, Pandya A, Thompson D, Langston AA, Perfect JR, Papadopoulos G.

Am J Health Syst Pharm. 2012 Jan 15;69(2):149-56. doi: 10.2146/ajhp110149.

PMID:
22215361
8.

Posaconazole vs fluconazole/itraconazole in the prophylaxis of invasive fungal infections in immunocompromised patients: a cost-effectiveness analysis in Greece.

Athanasakis K, Petrakis I, Kyriopoulos J.

J Med Econ. 2013;16(5):678-84. doi: 10.3111/13696998.2013.781028. Epub 2013 Mar 13.

PMID:
23448409
9.

Adapting a global cost-effectiveness model to local country requirements: posaconazole case study.

Papadopoulos G, Hunt S, Prasad M.

J Med Econ. 2013;16(3):374-80. doi: 10.3111/13696998.2012.761633. Epub 2013 Jan 8.

PMID:
23256900
10.

Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States.

O'Sullivan AK, Pandya A, Papadopoulos G, Thompson D, Langston A, Perfect J, Weinstein MC.

Value Health. 2009 Jul-Aug;12(5):666-73. doi: 10.1111/j.1524-4733.2008.00486.x.

11.

Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.

Cho SY, Lee DG, Choi JK, Lee HJ, Kim SH, Park SH, Choi SM, Choi JH, Yoo JH, Kim YJ, Kim HJ, Min WS, Back H, Kang S, Lee EK.

Clin Ther. 2015 Sep;37(9):2019-27. doi: 10.1016/j.clinthera.2015.06.014. Epub 2015 Jul 15.

12.
13.
14.

Cost-effectiveness of primary antifungal prophylaxis with posaconazole versus itraconazole in allogeneic hematopoietic stem cell transplantation.

Sánchez-Ortega I, Patiño B, Muñoz C, Arnan M, Peralta T, Clopés A, de Sevilla AF, Duarte RF.

J Med Econ. 2013;16(6):736-43. doi: 10.3111/13696998.2013.791301. Epub 2013 Apr 12.

PMID:
23541251
15.

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.

Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D.

N Engl J Med. 2007 Jan 25;356(4):348-59.

16.

Network Meta-analysis and Pharmacoeconomic Evaluation of Fluconazole, Itraconazole, Posaconazole, and Voriconazole in Invasive Fungal Infection Prophylaxis.

Zhao YJ, Khoo AL, Tan G, Teng M, Tee C, Tan BH, Ong B, Lim BP, Chai LY.

Antimicrob Agents Chemother. 2015 Nov 2;60(1):376-86. doi: 10.1128/AAC.01985-15. Print 2016 Jan.

17.

Cost effectiveness of posaconazole in the prophylaxis of invasive fungal infections in acute leukaemia patients for the French healthcare system.

Michallet M, Gangneux JP, Lafuma A, Herbrecht R, Ribaud P, Caillot D, Dupont B, Moreau P, Berger P, O'Sullivan AK.

J Med Econ. 2011;14(1):28-35. doi: 10.3111/13696998.2010.542393. Epub 2010 Dec 23.

PMID:
21175376
18.

Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain.

Grau S, de la Cámara R, Sabater FJ, Jarque I, Carreras E, Casado MA, Sanz MA.

BMC Infect Dis. 2012 Apr 3;12:83. doi: 10.1186/1471-2334-12-83.

19.

Cost-Effectiveness of Posaconazole Tablets for Invasive Fungal Infections Prevention in Acute Myelogenous Leukemia or Myelodysplastic Syndrome Patients in Spain.

Cámara R, Gozalbo I, Jurado M, Sanz J, Aragón B, Grau S.

Adv Ther. 2017 Sep;34(9):2104-2119. doi: 10.1007/s12325-017-0600-1. Epub 2017 Aug 14.

20.

An update to the cost-effectiveness of posaconazole vs fluconazole or itraconazole in the prevention of invasive fungal disease among neutropenic patients in the United States.

Sung AH, Marcella SW, Xie Y.

J Med Econ. 2015 May;18(5):341-8. doi: 10.3111/13696998.2014.1000460. Epub 2015 Mar 2.

PMID:
25524741

Supplemental Content

Support Center